Last reviewed · How we verify
NCT06696131: TNK in ICH
Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)
Phase 1 trial testing TNK in Intracerebral Hemorrhage in 5 participants. Not yet recruiting.
15 January 2027
Quick facts
| Lead sponsor | Gaurav Gupta, MD |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 15 September 2025 |
| Primary completion | 15 January 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- TNK — full drug profile →
Conditions studied
- Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →
- Intracranial Hemorrhages — all drugs for Intracranial Hemorrhages →
- Hemorrhagic Strokes — all drugs for Hemorrhagic Strokes →
Sponsor
Gaurav Gupta, MD
Who can join
Adults 18 to 80, any sex, with Intracerebral Hemorrhage or Intracranial Hemorrhages. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06696131
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TNK
Trials testing the same drug.
- NCT07168278 — Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT · Phase 3 · not yet recruiting
Other recruiting trials for Intracerebral Hemorrhage
Currently open trials in the same condition.
- NCT07458880 — Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control · NA · recruiting
- NCT07365150 — Precision Use of TXA in Intracerebral Hemorrhage · NA · recruiting
- NCT07246473 — Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage · NA · recruiting
- NCT07455201 — Evaluating a Prototype CT Scan for ICH Evacuation · NA · recruiting
- NCT07187687 — TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06696131 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gaurav Gupta, MD
- Last refreshed: 23 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06696131.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing